Myomo (MYO) Q2 2026 earnings review
Operating Leverage Kicks In as Channel Pivot Pays Off
Myomo delivered a textbook quarter of operating leverage. Revenue jumped 21% YoY to $11.7 million, fueled by the strategic shift toward recurring referral networks like MyoConnect and O&P channels. Because management kept operating expenses completely flat (+0.5% YoY), this volume growth flowed directly to the bottom line. Gross margin surged 940 basis points to 72.1% due to new tech deployments, causing the Adjusted EBITDA loss to collapse by 79% to just $0.8 million. While a $1.2 million non-cash derivative charge obscured progress on the GAAP net income line, the core operational trajectory is clearly accelerating toward cash-flow breakeven. Following the beat, management confidently raised full-year revenue guidance to $45-$47 million.
🐂 Bull Case
The 940 bps YoY jump in gross margin (reaching 72.1%) proves that recent product innovations—specifically the rollout of the Myomo Mobile App—are successfully stripping structural material costs out of the product.
Recurring patient sources now account for 53% of revenue (up from 26% a year ago). This shift has allowed the company to grow the top line 21% while keeping OpEx completely flat, fundamentally proving the business model can scale.
🐻 Bear Case
Despite a 23% jump in current orders, the company added only 739 patients to the pipeline in Q2—a decline compared to the 816 patients added in the same quarter last year. This creates potential risk for 2027 revenue growth.
GAAP Net Loss of $4.0M remains sticky, dragged down by rising interest expenses ($0.54M) and a $1.2M mark-to-market derivative hit. This volatility complicates the clean operating narrative.
⚖️ Verdict: 🟢
Bullish. The flat OpEx profile combined with a massive 940 bps gross margin improvement demonstrates that Myomo's strategic shift is working perfectly. The rapid 79% reduction in EBITDA loss overshadows the non-cash noise on the net income line.
Key Themes
MyoConnect and O&P Channel Momentum
Accelerating. The pivot away from high-cost direct-to-consumer advertising is yielding excellent results. Revenue from recurring patient sources (MyoConnect referrals, O&P partners, and the VA) reached 53% of total revenue, up sharply from 26% in the prior year. Notably, the U.S. O&P sales channel grew an explosive 130% YoY, proving that the strategy of leveraging third-party clinical networks is drastically lowering customer acquisition friction.
Myomo Mobile App Powers Gross Margin Surge
Accelerating. The company delivered a stunning 940 basis point YoY expansion in gross margins, climbing from 62.7% to 72.1%. This was primarily driven by the full rollout of the Myomo Mobile App, a technology innovation that eliminated the historical need to ship a laptop computer with every MyoPro device. This structural cost reduction directly enabled the 79% improvement in Adjusted EBITDA.
Unlocking Commercial Payer Access
Stable. The company continues to successfully dismantle payer bottlenecks. The multi-state agreement with Elevance's Anthem Blue Cross Blue Shield network saw additional state contracts completed in Q2. Combining commercial, Medicare, and VA patients, Myomo now has in-network access to over 100 million covered lives, leading to a record 255 orders in the quarter (+23% YoY).
Pipeline Additions Contradicting Growth Narrative
Decelerating. While the revenue and order conversion narrative is overwhelmingly positive, top-of-funnel pipeline metrics warrant scrutiny. The company added 739 patients to the pipeline in Q2 2026. This is essentially flat sequentially (vs 723 in Q1 2026) and notably lower than the 816 patients added in Q2 2025. If the shift away from broad social media advertising is permanently shrinking the top-of-funnel volume, it could cap future revenue velocity despite better conversion rates.
Below-The-Line Volatility Dragging Net Income
Reversing. Despite the massive operational beats, GAAP Net Loss widened sequentially from $3.0M in Q1 2026 to $4.0M in Q2 2026. This was entirely due to non-operating factors: a $1.2M non-cash charge for the mark-to-market of derivative liabilities (warrants) and $0.54M in interest expense on the debt facility. While non-cash, the derivative liabilities represent an ongoing headwind to clean GAAP profitability.
Medicare Advantage Macro Headwinds
Stable. While not explicitly broken out in the current press release, previous quarters heavily highlighted the macro friction caused by Medicare Advantage (MA) pre-authorization denial rates. Investors should monitor if the shift to recurring channels (MyoConnect) is effectively bypassing the MA bottleneck by delivering higher-quality, pre-qualified clinical documentation.
Other KPIs
Stable. The defining metric of the quarter. Operating expenses increased less than 1% YoY despite revenue growing 21%. Selling, clinical, and marketing expenses were held perfectly flat YoY at $5.26M, proving the company has broken its historical reliance on expensive direct-to-consumer ad spend to drive growth.
Stable. Up 2% YoY, but sequentially lower than Q1's elevated $58,800. This aligns with management's prior commentary that channel mix shifts (more O&P and international sales) would gradually normalize the ASP closer to the $55k range.
Accelerating. Cash used in operating activities saw a dramatic improvement, falling to just $1.9 million in Q2 2026 compared to a burn of $8.9 million in the same period last year. The company finished the quarter with $13.5 million in liquidity.
Guidance
Accelerating. The midpoint of $11.75M implies a ~16% YoY growth rate. Management noted they expect 'modestly higher operating expenses on a sequential basis' to fund the continued expansion of the MyoConnect program.
Accelerating. Raised from the previous expectation of $43M-$46M. H1 2026 revenue achieved $21.8M, meaning the guidance implies a strong H2 ramp to roughly $24.2M (at the midpoint) to meet the full-year target.
Accelerating. This target suggests the company expects to reach near-breakeven cash flow by Q4, driven by the combination of higher H2 revenue volumes and the preservation of current operating leverage.
Key Questions
Pipeline Volume Dynamics
Given that Q2 2026 pipeline additions (739) were notably lower than Q2 2025 (816), is the drop entirely due to intentionally filtering out low-quality social media leads, or is there an unexpected deceleration at the top of the funnel?
Gross Margin Sustainability
With gross margins leaping to 72.1% largely thanks to the mobile app replacing laptop hardware, have we reached the ceiling for hardware cost reductions, or are there further COGS optimizations planned for H2?
Impact of Derivative Liabilities
The $1.2M mark-to-market charge on derivative liabilities weighed heavily on Q2 net income. Can you provide parameters on how the warrant liability valuation will fluctuate with the stock price moving forward?